Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Novartis AG (NYSE:NVS) is expanding its gene therapy footprint by acquiring a venture capital-backed company focusing on treating vision loss that can lead to blindness.

Novartis Expands Presence in Gene Therapy With Acquisition

The digital press release with multimedia content can be accessed here:

Novartis announces positive results from a Phase IV study showing superior tolerability and efficacy of Aimovig® (erenumab) compared with topiramate in migraine prevention

Basel, October 30, 2020 — Novartis today announced the receipt of marketing authorization from Japan's Ministry of Health, Labor and Welfare (MHLW) for Foundation for Biomedical Research and Innovation at Kobe ("FBRI") to manufacture and supply commercial Kymriah® (tisagenlecleucel) for patients in Japan. This approval makes FBRI the first and only approved commercial manufacturing site for CAR-T cell therapy in Asia.

Novartis expands Kymriah® manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia

CAMBRIDGE, Mass., Oct. 29, 2020 /PRNewswire/ -- Vedere Bio, Inc. (Vedere Bio), a stealth-stage company focused on advancing photoreceptor-protein-based optogenetic therapies that are delivered to the retina intravitreally to restore functional vision, announced today that it has been...

Novartis Acquires Vedere Bio, a Novel Optogenetics AAV Gene Therapy Company

Novartis AG (NYSE: NVS) announced Wednesday it has received the license for global rights to develop, manufacture, and commercialize two antiviral therapies of Molecular Partners AG (OTC: MLLCF), which may be efficacious against COVID-19. What Happened: Molecular Partners will be paid approximately $66 million upfront, $165 million upon Novartis agreeing to take options on both the therapeutic candidates, and significant royalties on sales, Novartis said in a statement.

Novartis Strikes Deal To Commercialize Molecular Partners' COVID-19 Drug Candidates

Basel, October 28 , 2020 — Novartis and Molecular Partners AG today announced a collaboration in the form of an option and license agreement to develop, manufacture and commercialize Molecular Partners' anti-COVID-19 DARPin® program, consisting of two therapeutic candidates, MP0420 and MP0423. The collaboration aims to leverage Molecular Partners' proprietary DARPin® technologies and Novartis broad expertise in global drug development, regulatory affairs, manufacturing and commercialization to rapidly advance the program in keeping with the unprecedented global urgency created by the pandemic.

Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19

Novartis (NVS) CEO, Vas Narasimham on Q3 2020 Results - Earnings Call Transcript

Novartis AG's (NVS) CEO Vas Narasimhan on Q3 2020 Results - Quick Version Earnings Call Transcript

Shares of Novartis (SIX: NOVN) fell almost 4% Tuesday after the Swiss pharmaceuticals company reported lower-than-expected sales in the third quarter.  Fundamental analysis: Higher income, lower sales Novartis elevated its operating profit outlook on Tuesday on predictions that healthcare systems would handle the second coronavirus wave better than the first.

Novartis stock price falls to 7-month lows on lower sales

Novartis' (NVS) third-quarter 2020 sales take a hit due to the coronavirus pandemic but earnings beat estimates.

Novartis' (NVS) Q3 Earnings Surpass Estimates, Sales Miss

Novartis earnings beat third-quarter views while sales came in light. Full-year revenue guidance was in line for the Swiss drug giant.

Novartis Earnings Top, Sales Miss; NVS Stock Falls

Basel, October 27 , 2020 - commenting on the quarter, Vas Narasimhan, CEO of Novartis, said:

Novartis delivers solid Q3 performance with 11% core operating income growth, net sales in line with prior year, strong pipeline progression. Upgrades full year core operating income guidance.

Basel, October 26 , 20 20 — Novartis today announced positive Phase II interim analysis results for iptacopan (LNP023), an investigational oral treatment for C3 glomerulopathy (C3G), presented at the virtually held American Society of Nephrology (ASN) 2020 Annual Meeting.

Novartis presents promising interim Phase II data of potential first-in-class oral therapy iptacopan (LNP023) in rare renal disease C3 glomerulopathy (C3G)

Novartis (NVS) gets orphan drug designation for branaplam (LMI070) in Huntington's disease.

Novartis (NVS) Gets Orphan Drug Tag for Huntington's Disease Drug

If approved, inclisiran will be the first and only small interfering RNA (siRNA) in Europe for patients with hypercholesterolemia or mixed dyslipidemia.

Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol

British American Tobacco

Nestle SA

Novo Nordisk

Roche Holding AG

SAP SE

Sanofi

Unilever

Vanguard FTSE Developed Markets ETF

Leading wealth managers including BlackRock, Merrill Lynch and Putnam are advising their clients to invest in foreign stocks to take advantage of better values overseas. And the market's best European stocks are one such store of value-priced diversification.

10 Best European Stocks for an Income-Rich Recovery

In a conversation with ‘Fast Company’ Editor-in-Chief Stephanie Mehta, Novartis CEO Vas Narasimhan explained why the world failed to respond to the pandemic—and how we can eventually get back to something resembling normal. There will be no silver bullet that brings COVID-19 to an end—not even a vaccine, said Novartis CEO Vas Narasimhan.

Novartis CEO: A vaccine will not magically save us from COVID-19

EAST HANOVER, N.J., Oct. 3, 2020 /PRNewswire/ -- Novartis today announced that results reinforcing the long-term safety and efficacy profile of Aimovig® (erenumab-aooe) in patients with episodic migraine (EM) are being presented at the Migraine Trust Virtual Symposium. Results from the...

Novartis announces five-year data that reinforce the safety and efficacy profile of Aimovig® (erenumab-aooe) in adult patients with episodic migraine

Amgen

Mallinckrodt PLC

A House committee has issued detailed reports about some of their drug price increases.

Congressional Committee Accuses Amgen and Peers of Hiking Drug Prices to Meet "Aggressive" Revenue Targets

Novartis (NVS) announces data from late-stage studies on Tafinlar, Mekinist and Piqray at ESMO 2020.

Novartis Announces Data on Tafinlar, Mekinist & Piqray at ESMO

Basel, September 19, 2020 — Novartis today announced results of the final overall survival (OS) analysis from the SOLAR-1 trial, which evaluated Piqray® (alpelisib) in combination with fulvestrant, compared to fulvestrant alone, in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer patients with tumors harboring a PIK3CA mutation. Piqray is the only treatment approved in Europe, the United States and 15 other countries specifically for people with HR+/HER2- advanced breast cancer with a PIK3CA mutation. These data will be presented as a late-breaking oral presentation during the ESMO Virtual Congress 2020.

Novartis Piqray® data show survival benefit for patients with HR+/HER2- advanced breast cancer with a PIK3CA mutation

Basel, September 19, 2020 — Novartis announced today detailed results from the Phase III COMBI-i trial evaluating the investigational immunotherapy spartalizumab (PDR001) in combination with the targeted therapies Tafinlar ®  (dabrafenib) and Mekinist ®  (trametinib) compared to Tafinlar + Mekinist alone1. The efficacy data achieved in the trial’s control arm among patients treated with Tafinlar + Mekinist represent the longest progression-free survival results (PFS) observed across multiple Phase III studies. The trial did not meet its primary endpoint of investigator-assessed progression-free survival (PFS) for patients treated with the investigational triplet therapy 1-4 . 

Novartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar® and Mekinist® in advanced melanoma

Although it’s one of the major pharmaceuticals, Novartis didn’t directly jump into the vaccine race. That might have been the best move for Novartis stock.

Why Novartis’ Absence From the Covid-19 Vaccine Race Is a Benefit

Novartis: Finally In Position To Make Share Price Gains It Deserves

A Milan judge has seized 2.3 million euros ($2.7 million) from pharmaceutical multinational Novartis as part of a fraud investigation, a document seen by Reuters shows.

News for Novartis Stock (NVS)